SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
DewDiligence_on_SI
To: DewDiligence_on_SI who wrote (51010)7/29/2019 3:11:39 PM
From: A.J. Mullen1 Recommendation  Read Replies (1) of 52153
 
Agreed, but even allowing for a 10% rise pre-announcement, an overall 15% premium that’s paid mostly in stock seems less than exciting to me. Granted EXAS has a better-looking chart than GHDX, but I’ve always liked Genomic’s story and I don’t see the fit between a screening company and one used to determine treatment in oncology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News